Cantor Fitzgerald Reaffirms Neutral Rating for Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “neutral” rating restated by investment analysts at Cantor Fitzgerald in a research note issued on Monday, Marketbeat Ratings reports. SRPT has been the subject of several other research reports. Wells Fargo & Company lowered their price objective on Sarepta Therapeutics from $115.00 to $100.00 and […]
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “neutral” rating restated by investment analysts at Cantor Fitzgerald in a research note issued on Monday, Marketbeat Ratings reports. SRPT has been the subject of several other research reports. Wells Fargo & Company lowered their price objective on Sarepta Therapeutics from $115.00 to $100.00 and […]
